Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronan T Swords

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
British Journal of Haematology|April 18, 2018
A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormoneJoaquin J Jimenez, Gina M DelCanto, Petra Popovics, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 2, 2017
Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemiaJennifer Chapman, Julia T Geyer, Mahsa Khanlari, et al.
Blood|March 6, 2010
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemiaRonan T Swords, Kevin R Kelly, Peter G Smith, et al.
Leukemia Research|March 11, 2021
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survivalJacqueline S Garcia, Ronan T Swords, Gail J Roboz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2021
Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid MalignanciesMina M Tayari, Helena G Dos Santos, Deukwoo Kwon, et al.
British Journal of Haematology|March 4, 2015
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 studyRonan T Swords, Harry P Erba, Daniel J DeAngelo, et al.
Journal of Clinical Pathology|May 25, 2011
A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsyRonan T Swords, Javier Anguita, Russell A Higgins, et al.
Blood|January 20, 2018
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AMLRonan T Swords, Steven Coutre, Michael B Maris, et al.
Leukemia Research|November 28, 2017
Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot studyRonan T Swords, Diana Azzam, Hassan Al-Ali, et al.
Leukemia Research|October 14, 2016
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 studyRonan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|April 18, 2018
A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormoneJoaquin J Jimenez, Gina M DelCanto, Petra Popovics, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 2, 2017
Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemiaJennifer Chapman, Julia T Geyer, Mahsa Khanlari, et al.
Blood|March 6, 2010
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemiaRonan T Swords, Kevin R Kelly, Peter G Smith, et al.
Leukemia Research|March 11, 2021
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survivalJacqueline S Garcia, Ronan T Swords, Gail J Roboz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2021
Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid MalignanciesMina M Tayari, Helena G Dos Santos, Deukwoo Kwon, et al.
British Journal of Haematology|March 4, 2015
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 studyRonan T Swords, Harry P Erba, Daniel J DeAngelo, et al.
Journal of Clinical Pathology|May 25, 2011
A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsyRonan T Swords, Javier Anguita, Russell A Higgins, et al.
Blood|January 20, 2018
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AMLRonan T Swords, Steven Coutre, Michael B Maris, et al.
Leukemia Research|November 28, 2017
Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot studyRonan T Swords, Diana Azzam, Hassan Al-Ali, et al.
Leukemia Research|October 14, 2016
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 studyRonan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Pageof 3